Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/3/2009

ith Clostridium difficile infection (CDI) were presented at the 47th Annual Meeting of the Infectious Diseases Society of America in October 2009. Clinical investigator Mark Miller, M.D., presented data showing that patients treated with fidaxomicin had a faster time to resolution of diarrhea compared to those treated with vancomycin. Faster time to resolution of diarrhea may reduce the spread of CDI in healthcare facilities and improve patients' quality of life. Clinical investigator Kate Mullane, D.O., presented data showing that treatment with fidaxomicin compared to vancomycin in patients also receiving concomitant antibiotics resulted in higher clinical cure rates, lower recurrence rates and improved global cure rates.
  • Seven fidaxomicin-related abstracts from Optimer's North American Phase 3 study were presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September 2009. The additional data presented highlight fidaxomicin's unique profile as a new antibiotic class with beneficial characteristics for treating CDI such as lower recurrence rates, reduced risk of vancomycin-resistant enteroccoci (VRE) acquisition, favorable pharmacokinetic profile, and a safety profile comparable to that of vancomycin.
  • The full data analysis from the second Phase 3 clinical study for Pruvel was presented at ICAAC in September 2009. Data presented by primary investigator Robert Steffen, M.D., showed that Pruvel shortened recovery time in adult travelers suffering from infectious diarrhea.
  • The United States Patent and Trademark Office recently issued a patent which covers the composition of matter of CEM-101/(OP-1068). CEM-101/(OP-1068) is a macrolide derivative originally developed by Optimer and licensed to Cempra Pharmaceuticals who recently completed a Phase 1 clinical trial for the treatment of respiratory infections.

    • About Optimer Pharmaceuticals

    Optimer Phar
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
    2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
    3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
    4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
    9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
    10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
    11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
    (Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
    (Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
    (Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
    Breaking Biology Technology:Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
    ...within government channels, WEST PORT, Conn., and...c. (ABH) and Regenesis Biomedical, Inc. announced ...magraft(R) within the United,States (US) governmen...Regenesis will provide its specialized sales force...eran,s Administration (VA), Department of Defense,...
    ...ical,Services, Inc. (NYSE: WST ) today announced ...er 2008 cash dividend of $0.14 per share. The,divi...s of record on July,23, 2008., About West Pharmac...ces, Inc. is a global manufacturer of,components a... stoppers and,seals for vials, and closures and di...
    ...l/Mixed tropic HIV patients with ...May 7 Pathway Diagnostics announces,nationwide av...ular,SensiTrop(TM) II assay, combining the sensiti...) technology with the specificity of molecular,seq...atus of HIV infected,patients. Pathway performs th...
    Other Biology Technology:Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R) 2Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R) 3Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay 2
    (Date:12/4/2009)CORVALLIS, Ore. According to an analysis of statewide data taken from 1998-2001, women in Oregon who made less than $50,000 a year were more than three times likely to report they were discriminated
    (Date:12/4/2009)Scientists from the Royal Botanic Gardens, Kew and the Natural History Museum believe that carnivorous behaviour in plants is far more widespread than previously thought, with many commonly grown plan
    (Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
    Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2Scientists think 'killer petunias' should join the ranks of carnivorous plants 2How nutrition affects healthy aging 2Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry 12429 1Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry 12429 2Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences 4524 1Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences 4524 2Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences 4524 3Malaria Vaccine Developer Sanaria Inc Receives 2009 Vaccine Industry Excellence Award for Best Early Stage Vaccine Biotech 4522 1Malaria Vaccine Developer Sanaria Inc Receives 2009 Vaccine Industry Excellence Award for Best Early Stage Vaccine Biotech 4522 2
    ...ion, Matches with Watch-list Databases and Reports...ch 9 Neurotechnology, a provider of high-precisio...ounced the availability of VeriLook Surveillance S...identification using live video streams from high-...riLook 3.2 SDK and other facial recognition system...
    ...ch 12 (OTC Bulletin Board: CICI) Communication In... a leading supplier of electronic signature soluti...al industry* and the recognized leader** in biomet...ancial results for the fourth quarter and the year...the three months ended December 31, 2008 were $843...
    ...tion growth in southern Nevada has placed increasi...80% of the state,s residents lived in southern Nev...eople. The dual concerns of this population boom a... conditions has created an urgent demand for offic... meet resident and visitor demand., Las Vegas oper...
    Other Biology News:VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 2VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 3Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 2Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 3Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 4Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 5Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 6Keeping golf courses green when fresh water is limited 2Keeping golf courses green when fresh water is limited 3
    Anti-Histone H2B, acetyl (Lys20) Antibody, Unconjugated from Cell Signaling Technology
    Rhodamine-B-isothiocyanate from Research Organics, Inc.
    Rabbit Anti-Human MMP-7, aminoterminal end active enzyme, Antibody, Unconjugated from CEDARLANE Laboratories Limited
    Mouse Anti-CD42d Monoclonal Antibody, Unconjugated, Clone CLB-SW16 (formerly 708) from Abcam
    Biology Products: